Predictive marker analysis of liquidity factors in peripheral blood at pre- and post-anti VEGF monoclonal antibody, bevacizumab, treatment in non- squamous non-small-cell lung cancer patients.

Predictive marker analysis of liquidity factors in peripheral blood at pre- and post-anti VEGF monoclonal antibody, bevacizumab, treatment in non- squamous non-small-cell lung cancer patients. - Predictive marker analysis of liquidity factors in peripheral blood at pre- and post-anti VEGF monoclonal antibody, bevacizumab, in non- squamous non-small-cell lung cancer patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006845

Enrollment

Registered

2011-12-06

Start date

2011-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Interventions

Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) non-squamous Non Small Cell Lung Cancer 2) Written Informed Consent

Exclusion criteria

Exclusion criteria: Decision of ineligibility by a physician.

Design outcomes

Primary

Measure	Time frame
Analysis of liquidity factors	—

Countries

Japan

Contacts

Public ContactSyosaku Nomura

Kansai Medical University First Department of Internal Medicine

nomurash@hirakata.kmu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026